Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis

Atherosclerosis. 2010 Feb;208(2):484-9. doi: 10.1016/j.atherosclerosis.2009.08.026. Epub 2009 Aug 21.

Abstract

Objective: We aimed at identifying which lipid factors drive vascular risk in statin-treated patients with coronary artery disease (CAD).

Methods: We recorded vascular events over 5.6 years in 491 consecutive statin-treated patients with angiographically proven stable CAD, covering 2750 patient-years.

Results: In the total population, low high-density lipoprotein (HDL) cholesterol (standardized adjusted HR 0.73 [0.60-0.89]; p=0.001), low apolipoprotein A1 (0.77 [0.65-0.92]; p=0.003), a small low-density lipoprotein (LDL) particle diameter (0.76 [0.64-0.91]; p=0.002), and high triglycerides (1.20 [1.05-1.38]; p=0.007) predicted vascular events, but not total cholesterol, LDL cholesterol, or apolipoprotein B. Factor analysis in the lipid profiles of our patients revealed an HDL-related factor and an LDL-related factor. Concordant with the results for individual lipid parameters, the HDL-related factor (0.69 [0.58-0.83]; p<0.001) but not the LDL-related factor (p=0.455) predicted vascular events. Patients with type 2 diabetes (T2DM; n=116) were at a higher vascular risk than non-diabetic subjects (38.6% vs. 24.1%; p<0.001), and like in the total population the HDL-related factor (0.59 [0.44-0.77]; p<0.001) but not the LDL-related factor (p=0.591) predicted vascular risk in diabetic patients.

Conclusions: The pattern of low HDL cholesterol, low apolipoprotein A1, small LDL particles, and high triglycerides drives vascular risk in statin-treated coronary patients, particularly in those with T2DM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Apolipoprotein A-I / blood
  • Apolipoprotein A-I / metabolism
  • Apolipoproteins B / metabolism
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / diagnosis*
  • Case-Control Studies
  • Cholesterol, LDL / metabolism
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / diagnosis*
  • Coronary Artery Disease / drug therapy*
  • Diabetes Complications / diagnosis
  • Diabetes Mellitus, Type 2 / diagnosis
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Lipoproteins, LDL / metabolism
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk
  • Triglycerides / metabolism

Substances

  • Apolipoprotein A-I
  • Apolipoproteins B
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, LDL
  • Triglycerides